IBJNews

Bribery scandals sap Lilly’s China growth

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. has been counting on torrid growth in China to help offset losses from patent expirations in other markets, but slower growth in the Chinese economy and bribery allegations against Lilly and two other drugmakers have hampered Lilly’s growth there.

The Indianapolis-based drugmaker reported Oct. 23 that its Chinese sales grew 11 percent—down from 14 percent in the first half of the year and a big drop from the 24-percent growth Lilly posted there last year.

Some of that decline is due to a general slowing in the Chinese economy. Gross domestic product grew 7.8 percent in China last year, its lowest level in 13 years, and has been slowing even more this year. Economists polled by Reuters expect growth in China this year of 7.6 percent.

“We saw really two dynamics playing out in China at the moment. One is just the overall slowdown in economic growth in China,” Lilly Chief Financial Officer Derica Rice told analysts during an Oct. 23 conference call. “And the second factor has been the impact of some of the current compliance discussions that are going on in the China marketplace here in the late second and third quarter.”

Those “compliance discussions” stem from three bribery scandals that emerged in China in the middle of the year.

The biggest case involves London-based GlaxoSmithKline plc, whose employees allegedly paid $490 million for spurious travel expenses and traded sexual favors to boost sales among Chinese health care organizations. Chinese authorities unveiled their allegations against GlaxoSmithKline in July, when they also detained four Glaxo employees.

In early August, Paris-based Sanofi-Aventis SA was alleged by a whistleblower to have paid about $280,000 in bribes to 503 doctors in the country.

Two weeks later, a Chinese newspaper reported that Lilly employees gave at least $4.9 million in kickbacks to Chinese doctors to prescribe diabetes drugs in Shanghai and the eastern province of Shanghai. The 21st Century Business Herald based its report on what it called a former senior manager of Lilly, which it referred to by a pseudonym.

Lilly officials said they were “deeply concerned” about the allegations and were investigating them.

Lilly told investors last week that the situation was worst in August, but appeared to improve in September.

“Some physicians seemed to be distancing themselves from MNCs [foreign drugmakers] and showing some reluctance to see MNC [sales] reps in August, which contributed to a challenging August, but September was better,” Lilly officials said in a statement.

Connecticut-based market research firm IMS Health reported that drug sales in China rose 16.8 percent from January through July, but the pace of growth slowed to 8.5 percent in August, according to data provided by Lilly. IMS has yet to release Chinese sales data for September.

Growth in China is critical for Lilly, because its best-selling drug Cymbalta will lose its U.S. patent in December, allowing cheaper generic versions to steal about three-quarters of its more than $5 billion in annual sales.

China provided Lilly more than $500 million in revenue last year—and Lilly’s China sales had doubled over the previous three years.

Rice, Lilly’s CFO, said he expects the sales to rebound from the bribery scandals, although he’s not sure when. Slower growth in China’s economy will be an ongoing challenge, Lilly officials said, but they still expect sales growth to remain in the “high-single-digit” range.

“Like in many other geographies, we have our challenges in China,” said Jacques Tapiero, the outgoing president of Lilly’s emerging-markets business, during an Oct. 3 presentation to investors and analysts. “There will be ups and downs, but the long-term trajectory is very clear and remains very attractive. We remain very committed to China and are fully focused on implementing our plans with high integrity.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Socialized medicine works great for white people in Scandanavia. It works well in Costa Rica for a population that is partly white and partly mestizo. I don't really see Obamacare as something aimed against whites. I think that is a Republican canard designed to elicit support from white people for republican candidates who don't care about them any more than democrats care about the non-whites they pander to with their phony maneuvers. But what is different between Costa Rica nd the Scandanavian nations on one hand and the US on the other? SIZE. Maybe the US is just too damn big. Maybe it just needs to be divided into smaller self governing pieces like when the old Holy Roman Empire was dismantled. Maybe we are always trying the same set of solutions for different kinds of people as if we were all the same. Oh-- I know-- that is liberal dogma, that we are all the same. Which is the most idiotic American notion going right back to the propaganda of 1776. All men are different and their differences are myriad and that which is different is not equal. The state which pretends men are all the same is going to force men to be the same. That is what America does here, that is what we do in our stupid overseas wars, that is how we destroy true diversity and true difference, and we are all as different groups of folks, feeling the pains of how capitalism is grinding us down into equally insignificant proletarian microconsumers with no other identity whether we like it or not. And the Marxists had this much right about the War of Independence: it was fundamentally a war of capitalist against feudal systems. America has been about big money since day one and whatever gets in the way is crushed. Health care is just another market and Obamacare, to the extent that it Rationalizes and makes more uniform a market which should actually be really different in nature and delivery from place to place-- well that will serve the interests of the biggest capitalist stakeholders in health care which is not Walmart for Gosh Sakes it is the INSURANCE INDUSTRY. CUI BONO Obamacare? The insurance industry. So republicans drop the delusion pro capitalist scales from your eyes this has almost nothing to do with race or "socialism" it has to do mostly with what the INSURANCE INDUSTRY wants to have happen in order to make their lives and profits easier.

  2. Read the article - the reason they can't justify staying is they have too many medicare/medicaid patients and the re-imbursements for transporting these patient is so low.

  3. I would not vote for Bayh if he did run. I also wouldn't vote for Pence. My guess is that Bayh does not have the stomach to oppose persons on the far left or far right. Also, outside of capitalizing on his time as U. S. Senator (and his wife's time as a board member to several companies) I don't know if he is willing to fight for anything. If people who claim to be in the middle walk away from fights with the right and left wing, what are we left with? Extremes. It's probably best for Bayh if he does not have the stomach for the fight but the result is no middle ground.

  4. JK - I meant that the results don't ring true. I also questioned the 10-year-old study because so much in the "health care system" has changed since the study was made. Moreover, it was hard to get to any overall conclusion or observation with the article. But....don't be defensive given my comments; I still think you do the best job of any journalist in the area shedding light and insight on important health care issues.

  5. Probably a good idea he doesn't run. I for one do not want someone who lives in VIRGINIA to be the governor. He gave it some thought, but he likes Virginia too much. What a name I cannot say on this site! The way these people think and operate amuses me.

ADVERTISEMENT